Salute e Benessere

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

Each Unit will consist of one (1) post-consolidation common share in the capital of the Company (each, a "Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a "Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Each Unit will consist…
PR Newswire
16/07/2025

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in…

Key Takeaways from the Menin Inhibitors Market Report Key Takeaways from the Menin Inhibitors Market Report Discover which indication is expected to grab the major menin inhibitors market share @Menin Inhibitors Market Report Menin Inhibitors Market Dynamics The menin inhibitors market is emerging as a highly promising area within oncology, particularly in the treatment of hematological malignancies. The primary driver for this market is therising prevalence of acute...
PR Newswire
15/07/2025

Alkermes to Report Second Quarter Financial Results on July 29, 2025

About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a…
PR Newswire
15/07/2025

The Board of Directors of Sobi exercises authorisation for repurchase of shares…

Today, the Board of Directors has resolved to, conditional upon subscription and payment by Svenska Handelsbanken AB, exercise the repurchase authorisation for the said purpose by repurchasing all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 16 July – 7 November 2025. Today, the Board of Directors has resolved to, conditional upon...
PR Newswire
15/07/2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – July 15, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 15, 2025, from Atlas Special…
Actusnews Wire
15/07/2025

Innovative Immunodiagnostic Platform Unveils Highly Sensitive Cancer…

Instead of hunting for tiny fragments of circulating tumour DNA, the platform measures fluctuations in specific amino acid residues - building blocks of immune proteins - in a simple blood sample. Instead of hunting for tiny fragments of circulating tumour DNA, the platform measures fluctuations in specific amino acid residues - building blocks of immune proteins - in a simple blood sample. Early-stage tumours often provoke a robust immune response before they shed enough DNA to be detected...
PR Newswire
15/07/2025

The New Science of Superhumans: The BioSport™ AI System Unlocks Hidden Athlete…

With elite advisors, cutting-edge genomics, and real-time AI, the sports health platform targets cardiac complications, overexertion injuries, flawed team selections, and untapped talent In the high-stakes world of elite sports, the difference between triumph and tragedy can hinge on a single, unseen biological flaw. A hidden cardiac risk. A lingering inflammation. A genetic predisposition to injury. These silent threats have ended promising careers and lives—sometimes on live television,...
Nasdaq GlobeNewswire
15/07/2025

Oral Care Market worth $53.29 billion by 2030 with 6.4% CAGR |…

Browse in-depth TOC on 'Oral Care Market'345 - Tables62 - Figures318 - Pages Browse in-depth TOC on 'Oral Care Market' 345 - Tables 62 - Figures 318 - Pages By product type,the oral care market can be categorized by product type into several key segments, including toothpaste, toothbrushes, mouthwashes/rinses, dental accessories, and denture products. As of 2024, the toothpaste segment dominated the market, capturing the largest share. This significant market presence can be...
PR Newswire
15/07/2025

Evestia Clinical to merge with Atlantic Research Group

Kester Capital-backed Evestia Clinical merges with US-based Atlantic Research Group (ARG) to create a leading independent global specialist CRO in fast-growing marketsThe merger delivers on Evestia Clinical’s strategy of targeted growth through the expansion of services, enhanced technology and broadened geographical reachEvestia Clinical expands footprint in the US and strengthens its offering beyond oncology, rare diseases, immunology and inflammation to include neurology and...
Nasdaq GlobeNewswire
15/07/2025

Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy…

Media.Market.us continued: "Enhanced Patient Monitoring through AI: AI-powered tools are revolutionizing the monitoring of retinal diseases. These tools enable continuous observation, allowing doctors to track disease progression over time. This ongoing monitoring is crucial for chronic conditions, where timely adjustments to treatment can lead to better management of the disease. Continuous data collection provided by AI tools offers a dynamic view of the patient's condition, facilitating…
PR Newswire
15/07/2025

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset…

AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutationCELESTE is informed by the STELLA prospective natural history study, which is currently enrolling patients in the United States and EuropeAAVB-039 uses AAVantgarde’s proprietary dual AAV intein platform. The platform has achieved unprecedented preclinical data demonstrating high transduction, protein expression, and safety in...
Nasdaq GlobeNewswire
15/07/2025

Elsevier's Clinician of the Future 2025 survey: Clinicians' AI usage and…

Physicians and nurses are optimistic about the potential of AI to improve patient care in the next two to three years. Based on 2,206 survey responses from 109 countries, clinicians are most optimistic about the potential of clinical AI tools to save them time (70%), enhance diagnostic speed (58%) and accuracy (54%), and help improve patient outcomes (55%). Physicians and nurses are optimistic about the potential of AI to improve patient care in the next two to three years. Based on 2,206...
PR Newswire
15/07/2025

Navamedic ASA: Closing of the transaction to acquire the business of dne pharma

The Acquisition encompasses dne pharma's business, including product portfolio, key employees and all essential contracts of the business, intellectual property, licenses, and distribution agreements. The product portfolio includes prominent products such as Ventizolve® (intranasal naloxone spray for opioid overdose reversal), Levopidon® (levomethadone), and Metadon Dne (methadone) for opioid substitution therapy. The acquired business will be integrated into Navamedic's existing commercial…
PR Newswire
15/07/2025

Bridge to Life™ Unveils Groundbreaking 12-Month Clinical Trial Data on HOPE at…

The following are scheduled presentations at WTC 2025: The following are scheduled presentations at WTC 2025: Plenary SessionPresentation Title:Hypothermic-Oxygenated and Normothermic Machine Perfusion: A Risk-Matched Post-Hoc Comparison of the Bridge to Hope Randomized Trial with Prospectively Collected Institutional OutcomesDate: Monday, August 4 th Time:10:30 AM -10:45 AM PT Presenter: Chase J. Wehrle, MD, Cleveland Clinic,Cleveland, OH ILTS 2025 Young Investigators...
PR Newswire
15/07/2025

New TriNetX Survey Reveals Biopharma's Bold Embrace of Real-World Data and…

The survey, which polled 150 senior executives across pharma and biotech, found that: The survey, which polled 150 senior executives across pharma and biotech, found that: "Real-world data is no longer a concept, it's a capability," saidSteve Kundrot, Chief Operating Officer at TriNetX. "The leaders we surveyed see its value and are investing in execution. But to fully realize real-world data's promise, we must tackle integration challenges, enforce data standards, and build trust…
PR Newswire
15/07/2025

Argon Medical Streamlines Distribution of Product and Enhances Customer Training…

This major investment underscores Argon Medical's commitment to enhancing customer service, operational excellence, and clinical support amid the rapid growth of the EMEA and APAC markets. By streamlining logistics and providing comprehensive education, the new facility is poised to accelerate product shipments, increase responsiveness, and foster stronger, more collaborative partnerships with regional stakeholders. This major investment underscores Argon Medical's commitment to enhancing...
PR Newswire
15/07/2025

Lunar Mineralogram: Daphne Lab® Unveils AI-Powered Bioenergetic Test for…

Daphne Lab® introduces the Lunar Mineralogram, a revolutionary update to its bioenergetic analysis platform, developed within the framework of the Lunar Project. The new test features advanced AI-driven indicators, novel toxicological profiles, and cutting-edge algorithmic processing. Key innovations include the IBR (Isotopic Balance Ratio) and EMPI (Electrometallopathy Index), along with a broadened panel of trace elements.
Daphne Lab
15/07/2025

Esaote North America, Inc. Honored at Premier, Inc.'s Annual Supplier Innovation…

"It's an honor to have the O-scan SMART recognized as an Innovation Celebration award winner," says Stephen Gibbs, Director of Sales and Marketing at Esaote North America, Inc. "Adding extremity MRI to your imaging services offers a smart, cost-effective investment. With lower installation and operating costs compared to conventional systems, extremity MRI helps facilities reduce patient backlogs, control costs, and expand access to care to everyone, everywhere." "It's…
PR Newswire
15/07/2025

Gen Phoenix Secures $15M Investment Round as Tapestry Expands Strategic…

"This expanded partnership marks a major milestone—not just for Gen Phoenix, but for the future of sustainable materials," said John Kennedy, CEO of Gen Phoenix. "Together with Tapestry, we're proving that circular innovation can meet the demands of global brands without compromise. It's a powerful example of what happens when you combine material innovation, leather heritage, shared values, and a commitment to scale." "This expanded partnership marks a major…
PR Newswire
15/07/2025

Second Edition of Ketamine-Assisted Therapy Training in Barcelona

The Ketamine Research Foundation (USA) and Clínica Synaptica present the second edition of the Ketamine-Assisted Psychotherapy (KAP) Training, a pioneering program in Europe that strengthens an innovative mental health approach already established in the USA and Canada. KAP, which combines ketamine administration with psychotherapy, is transforming the treatment of disorders such as treatment-resistant depression, anxiety disorders, post-traumatic stress disorder, and chronic pain by inducing…
PR Newswire
15/07/2025

Baraya Extended Care Closes Series B Funding Round Bringing Total Capital Raised…

This fundraise comes at a critical moment, as Saudi Arabia faces a rapidly aging population, rising incidences of chronic conditions, and increased demand for specialized post-acute care driven by the Kingdom's ambitious Vision 2030 and Health Sector Transformation Program. According to the Saudi Ministry of Health, 14% of acute care beds in public hospitals are occupied by long-stay (long-term care) patients. This figure is even higher in some regions, such as Jeddah (19%) and Riyadh (17%). ...
PR Newswire
15/07/2025

Topflight Pharma Development Veteran Joins Synendos

Dr. George Garibaldi is named Chief Medical Officer (CMO) as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy Synendos CEO, Andrea Chicca said, "It’s tremendous that Synendos can attract this calibre of talent and experience. George offers a nuanced clinical perspective on the urgent needs of the patients we are looking to help, combined with specific expertise in advancing transformative neuroscience therapies from concept to clinical adoption.”Dr...
Nasdaq GlobeNewswire
15/07/2025

Da Vinci’s Vitruvian Man Encodes the Blueprint of Human Evolution, Says London…

New research reveals a hidden geometric ratio in Leonardo’s drawing that may define the endpoint of human evolution toward upright posture Photo Courtesy of Rory Mac Sweeney LONDON, July14, 2025(GLOBE NEWSWIRE) -- A London-based dental surgeon and researcher, Dr. Rory Mac Sweeney of Precision Endodontics, has ignited international interest with a provocative reinterpretation of Leonardo da Vinci’s Vitruvian Man. His newly published research suggests the Renaissance masterpiece...
Nasdaq GlobeNewswire
15/07/2025

MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast…

Key Takeaways from the MCR Therapies Market Report Key Takeaways from the MCR Therapies Market Report Discover which indication is expected to grab the major MCR therapies market share @MCR Therapies Market Report MCR Therapies Market Dynamics The MCR therapies market is emerging as a promising therapeutic area, driven byadvancements in understanding melanocortin receptor biologyand its involvement in multiple disease pathways. MCRs, which include five distinct receptor...
PR Newswire
14/07/2025
Altri  Comunicati